Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss – Medscape
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss Medscape China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study finds Reuters Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug Bloomberg SLIMMER: Ecnoglutide Demonstrates Weight Loss Potential in Phase 3 Trial HCPLive China, where obesity levels are low, becomes hotbed for weight loss drug trials STAT
Decision on merger with Biocon Biologics soon, says Siddharth Mittal
We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal
Lilly’s Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines, in Complete Phase 3 Results
INDIANAPOLIS, June 21, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and…
200,000 people can now get weight loss jab from their GP
Mounjaro weight loss jab will now be available on the NHS (Picture: Getty Images) GPs will be allowed to prescribe weight loss jabs for the first time from Monday. The mass rollout will see around 220,000 people with the ‘greatest need’ receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. […]